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WZB117 (2-fluoro-6-(m-hydroxybenzoyloxy) phenylm-hydro-
xybenzoate) inhibits passive sugar transport in human eryth-
rocytes and cancer cell lines and, by limiting glycolysis, inhib-
its tumor growth in mice. This study explores how WZB117
inhibits the erythrocyte sugar transporter glucose transport
protein 1 (GLUT1) and examines the transporter isoform spec-
ificity of inhibition. WZB117 reversibly and competitively
inhibits erythrocyte 3-O-methylglucose (3MG) uptake with
Ki(app)  6 M but is a noncompetitive inhibitor of sugar exit.
Cytochalasin B (CB) is a reversible, noncompetitive inhibitor of
3MG uptake with Ki(app) 0.3M but is a competitive inhibitor
of sugar exit indicating that WZB117 and CB bind at exofacial
and endofacial sugar binding sites, respectively. WZB117 inhi-
bition of GLUTs expressed in HEK293 cells follows the order
of potency: insulin-regulated GLUT4  GLUT1 ≈ neuronal
GLUT3.Thismay explainWZB117-inducedmurine lipodystro-
phy. Molecular docking suggests the following. 1) TheWZB117
binding envelopes of exofacial GLUT1 and GLUT4 conformers
differ significantly. 2) GLUT1 andGLUT4 exofacial conformers
present multiple, adjacent glucose binding sites that overlap
with WZB117 binding envelopes. 3) The GLUT1 exofacial
conformer lacks a CB binding site. 4) The inward GLUT1
conformer presents overlapping endofacial WZB117, D-glu-
cose, and CB binding envelopes. Interrogating the GLUT1
mechanism usingWZB117 reveals that subsaturatingWZB117
and CB stimulate erythrocyte 3MG uptake. Extracellular
WZB117does not affect CBbinding toGLUT1, but intracellular
WZB117 inhibits CB binding. These findings are incompatible
with the alternating conformer carrier for glucose transport but
are consistent with either amultisubunit, allosteric transporter,
or a transporter in which each subunit presents multiple, inter-
acting ligand binding sites.
Most cancer cells use anaerobic metabolism (glycolysis) to
generate the ATP required for cellular processes and prolifera-
tion (1). This contrasts with normal, differentiated cells, which
mostly use mitochondrial oxidative phosphorylation to sustain
cellular function (2). The transition from aerobic to anaerobic
metabolism is termed “the Warburg effect” and is driven by
growth conditions, by mutations of proto-oncogenes and
tumor-suppressor genes (2, 3). Vander Heiden et al. (1) have
proposed that the metabolism of all proliferating cells (includ-
ing cancer cells) is adapted to enhance nutrient uptake and
nutrient incorporation into the biomass needed to produce a
new cell. This would explain why the developing central nerv-
ous system is so susceptible to glucose deprivation resulting
fromglucose transport-deficiency at the blood-brain barrier (4)
and why cancer cells are so sensitive to limited glucose avail-
ability (5).
This has prompted several groups to propose that suppress-
ing anaerobic metabolism may offer an effective anti-cancer
strategy. Three approaches have been used to limit glycolysis
in cancer cells; that is glucose deprivation in vitro (6, 7), the
in vitro and in vivo use of glycolysis inhibitors (8), and cellu-
lar glucose transport inhibition in vitro and in vivo (8, 9). All
three approaches cause cancer cell death.
Glucose transport in most mammalian cells is catalyzed by
one or more members of the GLUT2 (SLC2A) family of passive
glucose transporters (10). GLUT1 (the blood brain barrier/
erythroid glucose transporter) and, in some instances, GLUT3
(the neuronal glucose transporter) or GLUT12 expression is
significantly increased in proliferating cells (11).
Successful strategies for passive glucose transport inhibition
have exploited a range of molecules that bind at or close to
either the exofacial (e.g. maltose, ethylidene glucose) or the
endofacial sugar binding site (e.g. cytochalasin B; Refs. 12–14).
A number of unrelated inhibitory molecules react with the
GLUT1 purine binding site (e.g.ATP, AMP, caffeine; Ref. 15) or
at other, less well defined sites (e.g. androgens, quercetin; Refs.
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16 and 17). These and relatedmolecules have been suggested as
potential scaffolds for designing inhibitors of glucose uptake in
cancer cells or cancer stem cells (8, 18–20).
Using such an approach, Zhang et al. (21) identified a class
of polyphenolic compounds with sugar transport inhibitory
potency. Among these, WBZ117 (2-fluoro-6-(m-hydroxyben-
zoyloxy)phenylm-hydroxybenzoate) showed the highest affin-
ity for sugar transport inhibition and inhibited tumor growth in
a nude mouse model (9).
Although a promising strategy for cancer cell elimination,
glucose transport inhibition in vivomay present several attend-
ant complications. These include impaired insulin secretion,
elevated blood glucose, diuresis, elevated glycation, impaired
glucose transport across the blood-brain barrier, and reduced
metabolic capacity in healthy cells that depends upon glycolysis
for normal function. We, therefore, undertook a systematic
analysis of WZB117 inhibition of glucose transport.
We found that WZB117 interacts with GLUT1 at the exofa-
cial sugar binding site and thus acts as a reversible, competitive
inhibitor of net glucose uptake and exchange glucose transport
but as a noncompetitive inhibitor of sugar efflux from cells.
WZB117 inhibits the insulin-sensitive glucose transport
(GLUT4) with greater potency than its inhibition of either
GLUT1 or GLUT3.
Results
Sugar transport in human erythrocytes is catalyzed by
GLUT1 (22). Transport theory states that ligands binding
reversibly at the exofacial sugar binding site act as competitive
inhibitors of sugar uptake and as noncompetitive inhibitors of
exit. Conversely, ligands binding reversibly at the endofacial
sugar binding site act as noncompetitive inhibitors of sugar
uptake and as competitive inhibitors of exit (23–25).
To understandwhetherWZB117 inhibitsGLUT1 by binding
at the exofacial or endofacial sugar binding site, we examined its
effects on three modes of erythrocyte sugar transport: zero-
trans 3MG uptake (uptake into cells lacking sugar), zero-trans
3MG exit (efflux from cells into medium lacking sugar), and
equilibrium exchange 3MG uptake (unidirectional uptake of
3MG in cells where [3MG]i [3MG]o).
WZB117 inhibits zero-trans 3MG (0.1 mM) uptake by eryth-
rocytes in a dose-dependentmannerwithKi(app) 6.2 1.6M
(Fig. 1). CB (a known GLUT1 endofacial site ligand) inhibits
0.1 mM 3MG zero-trans uptake with Ki(app)  0.3  0.1 M
(see Fig. 4).
We assessed the reversibility of inhibition in two ways. The
first method involved exposing RBCs to buffer containing or
lackingWZB117 (3M) or CB (0.5M) for 10min, then remov-
ing the inhibitors using a centrifugation/wash cycle and incu-
bating the cells in inhibitor-free buffer for a further 15min.We
then measured 0.1 mM 3MG uptake in these cells. WZB117 (3
M) or CB (0.5M) inhibit sugar uptake by 50% (Fig. 2). Remov-
ing the inhibitor before sugar uptake determinations restored
sugar uptake to levels of 75% or greater of uninhibited controls
(Fig. 2).
WZB117 Is a Competitive Inhibitor of 3MGUptake by Human
Erythrocytes—The second method of assessing reversibility of
inhibition evaluates the type of sugar transport inhibition pro-
duced byWZB117. Competitive inhibitors act by binding revers-
ibly either to the active site of an enzyme or to a site whose occu-
pancy occludes occupancy of the active site and vice versa (26).
Preincubation with WZB117 (7 M) before initiation of
transport measurements increased Km(app) for zero-trans 3MG
uptake from 1.0 0.2 mM to 2.8 0.4 mM, but Vmax for 3MG
uptake (0.59  0.03 mmol/liter of cell water/min) was unaf-
fected (Fig. 3). This result indicated that WZB117 is a compet-
itive inhibitor of human erythrocyte sugar uptake. If WZB117
bound irreversibly to the active site, preincubation with the
FIGURE 1. Sensitivity of zero-trans 3MG (0.1 mM) uptake by erythrocytes
to inhibition byWZB117. Ordinate: 3MG uptake in mmol/liter of cell water/
min.Abscissa: WZB117 inM. Eachdata point represents themean S.E. of at
least three separate measurements made in duplicate. The curves drawn
through thepointswere computedbynonlinear regression assuminguptake
is inhibited completely by inhibitor in a dose-dependent manner (see Equa-
tion 1). The results are: Ki(app)  6.2  1.6 M, R
2  0.946, standard error of
regression 0.0021 mmol/liter of cell water/min.
FIGURE2.Reversibilityof transport inhibitionbyWZB117andbyCB.Ordi-
nate: 3MG uptake in mmol/liter of cell water/min. Abscissa: experimental
treatment. Control cells saw no inhibitor during sugar uptake; WZB117 and
CB cells were exposed to inhibitor (3M WZB117 and 0.5M CB respectively)
for 15 min on ice before measurement of 3MG uptake in the presence of
inhibitor. WZB117 -washout and CB-washout cells were exposed to inhibitor
(3 M WZB117 and 0.5 M CB, respectively) for 15 min on ice followed by
inhibitor removal and exposure to inhibitor-free medium for 15 min on ice
and finally measurement of 3MG uptake in the absence of inhibitor. Each
symbol (F) represents the mean of duplicate measurements. The horizontal
lineand error bars represent themeanS.E. of each condition.Unpaired t test
analysis indicates:, transport under all treatments is significantly lower (p
0.005) than in control cells;, transport after washout treatment is signifi-
cantly greater (p 0.005) than in the correspondingnon-washout treatment.
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inhibitor would most likely have reduced Vmax for transport in
addition to increasing Km(app).
Conversely, CB (0.7 M) reduces Vmax for 3MG uptake
(0.29 0.05 mmol/liter of cell water/min) but has no effect on
Km(app) (Fig. 3A). This result confirms that CB is a noncompet-
itive inhibitor of uptake and is expected for an inhibitor which
binds reversibly to the endofacial active site (25).
WZB117 Is a Noncompetitive Inhibitor of Net Sugar Exit—
BecauseWZB117 competes for 3MG binding at or close to the
exofacial sugar entry site, we hypothesized thatWZB117would
act as a noncompetitive inhibitor of sugar exit (25). To this end,
we performed sugar exit experiments where we measured the
time course of zero-trans sugar exit from pre-loaded red cells
into sugar-free external medium. The time course of exit was
analyzed by simulating sugar exit by numerical integration
using BerkeleyMadonna software assumingMichaelis-Menten
exit kinetics then adjusting simulated Michaelis-Menten
parameters using the Levenberg-Marquardt algorithmuntil the
fits between simulated and experimental exit data were opti-
mal. Our analysis shows that WZB117 (0.7 M) reduces Vmax
for 3MG exit from 2mmol/liter of cell water/min to 0.8 mmol/
liter of cell water/min, whereas Km(app) for exit (15 mM) was
unaffected (Fig. 3B). Consistent with published data (13), CB
(0.7M) was competitive for sugar exit, increasingKm(app) to 47
mM with no effect on Vmax (Fig. 3C).
WZB117 Is a Competitive Inhibitor of Equilibrium Exchange
Sugar Transport—Equilibrium exchange 3MG transport in
human red blood cells ([3MG]i  [3MG]o) was competitively
FIGURE 3. Effects of WZB117 and CB on Michaelis-Menten kinetics of zero-trans 3MG uptake (A), zero-trans 3MG exit (B and C), and equilibrium
exchange 3MGuptake (D). Results are shown for control cells (E), WZB117-treated cells (F), and for CB-treated cells (‚). Each data point is themean S.E. of
three duplicate measurements. A, ordinate: 3MG uptake in mmol/liter of cell water/min. Abscissa: [3MG]o in mM. Curves drawn through the points were
computedbynonlinear regression assumingMichaelis-Mentenuptake kinetics (Equation 2) andhave the following results: control cells (E),Vmax 0.59 0.03
mmol/liter of cell water/min, Km(app) 1.05 0.16 mM, R
2 0.992, standard error of regression 0.018 mmol/liter of cell water/min; WZB117 treatment (F):
Vmax 0.68 0.04 mmol/liter of cell water/min, Km(app) 2.77 0.35 mM, R
2 0.997, standard error of regression 0.018 mmol/liter of cell water/min; CB
treatment (‚): Vmax 0.29 0.05 mmol/liter of cell water/min, Km(app) 1.67 0.63 mM, R
2 0.966, standard error of regression 0.010 mmol/liter of cell
water/min. B and C, ordinates: [3MG]i in mmol/liter of cell water. Abscissa: time In minutes. Curves drawn through the points were computed by nonlinear
regression and numerical integration assuming Michaelis-Menten exit kinetics and have the following results: Control cells (E): Vmax  2 mmol/liter of cell
water/min, Km(app) 15 mM; WZB117 treatment (F): Vmax 0.8 mmol/liter of cell water/min, Km(app) 15 mM; CB treatment (‚): Vmax 2 mmol/liter of cell
water/min, Km(app) 47 mM. D, Hanes-Woolf plot of equilibrium exchange transport. Ordinate: [3MG]/rate of equilibrium exchange 3MG uptake in minutes.
Abscissa: intracellular and extracellular [3MG] in mM. Lines drawn through the points were computed by nonlinear regression assuming that each line is
described by Equation 3. The results are: control cells (E): Vmax 13.39 0.79 mmol/liter of cell water/min, Km(app) 40.25 3.57 mM, R
2 0.990, standard
error of regression 0.17min;WZB117 treatment (F):Vmax 13.36 2.02mmol/liter of cell water/min, Km(app) 82.25 15.30mM, R
2 0.936, standard error
of regression  0.43 min; CB treatment (‚): Vmax  8.87  0.33 mmol/liter of cell water/min, Km(app)  49.85  2.55 mM, R
2  0.996, standard error of
regression 0.16 min.
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inhibited by WZB117. WZB117 (7 M) increased Km(app) for
3MG exchange transport from 40.25  3.57 mM to 82.25 
15.30mM but had no effect onVmax (13.39 0.79mmol/liter of
cell water/min; Fig. 3D). CB (0.7 M), however, was a mixed-
type inhibitor of equilibrium exchange 3MG transport reduc-
ing Vmax (8.87  0.33 mmol/liter of cell water/min) and
increasing Km(app) (49.85 2.56 mM; Fig. 3D).
Subsaturating Levels of CB and WZB117 Stimulate Sugar
Uptake in Human Erythrocytes—Previous studies have shown
that subsaturating concentrations of CB or exofacial inhibitors of
GLUT1produce amodest stimulationof erythrocyte sugaruptake
(27, 28). Subsaturating levels of CB (0.1 M) and WZB117 (0.1
M) stimulate zero-trans 3MG uptake in human erythrocytes by
up to 25% above untreated cells (Fig. 4). This effect is significant
(p  0.0075) at 10 and 50 nM CB and at 100 nM WZB117 (p 
0.001). CB and WZB117 may stimulate transport by reducing
Km(app) for sugar uptake (Table 1), but the data are not conclusive.
Effect of WZB117 on CB Binding—CB is membrane-per-
meant and rapidly crosses the cell membrane to interact with
the GLUT1 endofacial sugar binding site (23, 25). The simple
carrier hypothesis for facilitated diffusion predicts that CB and
WZB117 binding to GLUT1 are mutually exclusive (23–25).
Accordingly, CB should competitively inhibit WZB117 inhibi-
tion of and binding to GLUT1. The IC50 for CB inhibition of
3MGuptake (0.35M) is notmaterially affectedwhenWZB117
(5 M) is present (Fig. 4).
WZB117 iswithout effect on [3H]CBbinding to humanRBCs
but served as a low affinity inhibitor of CB binding to red cell
membranes depleted of peripheral membrane proteins (Fig. 5;
Ki(app)  156 24 M). RBC membranes depleted of peripheral
proteins are unsealed, and bothmembrane surfaces are accessible
to buffer (29). Collectively, these results indicate: 1) CB binding to
theGLUT1endofacial sugar binding site is insensitive toWZB117
binding at the exofacial sugar binding site; 2) CB and WZB117
compete for binding at the GLUT1 endofacial sugar binding site;
3) RBCs are impermeable toWZB117 because inhibition of bind-
ing by a membrane-permeantWZB117 would have been evident
inmeasurements with intact RBCs. In addition, these findings are
consistent with the actions of D-glucose on CB binding to RBCs;
extracellular D-glucose iswithout effect onbinding,whereas intra-
cellular D-glucose competitively inhibits binding (30).
Isoform Specificity of Transport Inhibition—The GLUT
(SLC2A) family of passive glucose transporters can show
distinct, isoform-specific affinities for inhibitors. For example,
FIGURE 4. CB andWZB117 stimulate 3MGuptake at subsaturating inhib-
itor concentrations. Ordinate: relative 3MG uptake. Abscissa: Inhibitor con-
centration in M. Results are shown for WZB117-treated cells (F), for
CB-treated cells (‚), and for cells exposed to CB plus 5 M WZB117 (Œ). Each
data point is the mean S.E. of three or more duplicate measurements. The
curves drawn through the points were computed by nonlinear regression
according to Equation 4 or Equation 1 and have the following constants:
WZB117-treated cells (F)1 0.152 0.056, K1 0.0014 0.0013M, K2
11.02.4M,R20.952, standarderror of regression0.09; CB-treated cells
(‚) 1  0.653  0.115, K1  0.012  0.011 M, K2  0.29  0.10 M, R
2 
0.974, standard error of regression  0.09; cells exposed to CB plus 5 M
WZB117 (Œ) vo 0.69 0.02, K1 0.46 0.07, R
2 0.986, standard error of
regression 0.02. The arrows represent IC50 for CB inhibition of transport in
the absence (solid lines) or presence (dashed lines) of 5 M WZB117 respec-
tively. Differences between transport in the absence and presence of each
concentration of inhibitor were analyzed by ordinary one-way ANOVA using
Dunnett’smultiple comparisons testwith a single pooled variance and a fam-
ily-wise significance and confidence level of 0.01. CB (10 and 50 nM) and
WZB117 (100 nM) significantly increased 3MG uptake. Transport inhibition is
significant at WZB1175 M and at CB250 nM.
FIGURE 5.WZB117 iswithout effect on [3H]CBbinding tohumanRBCs (F)
but serves as a lowaffinity inhibitor of CBbinding to red cellmembranes
depleted of peripheral membrane proteins (E). The lines drawn through
the points were computed by linear regression. Ki(app) for inhibition of CB
binding is computed as the -x-intercept. The results are: RBCs (F) Ki(app) 
373 310M, R2 0.238, p value testing the null hypothesis that the overall
slope is zero 0.2765; membranes (E) Ki(app) 150.4 24.4 M; R
2 0.943,
p value testing the null hypothesis that the overall slope is zero 0.0058.
TABLE 1
Effects of subsaturating inhibitors on 3MG uptake
TheMichaelis-Menten kinetics of 3MG (0.1–5mM) uptake by RBCs wasmeasured in paired experiments in the presence or absence ofWZB117 (0.7M) or CB (0.025M)
and analyzed by nonlinear regression using Equation 2. Each data point (uptake measured at each 3MG concentration) averaged three or more measurements made in
duplicate. R2 for all fits was0.994. Results are shown as the mean S.E. and as 95% confidence Intervals for Vmax and Km(app) under all conditions.
Experimental condition
Vmax Km(app)
Mean S.E. 95% Confidence interval Mean S.E. 95% Confidence interval
mmo/liter cell water/min mM
Control 0.63 0.01 0.59–0.68 2.26 0.12 1.92–2.68
WZB117 0.7 M 0.55 0.04 0.46–0.69 1.74 0.26 1.08–2.91
CB 0.025 M 0.60 0.02 0.55–0.67 1.73 0.13 1.36–2.23
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the insulin-sensitive glucose transporter of fat and muscle
(GLUT4) is inhibited by HIV protease inhibitors, but GLUT1 is
not (31), whereasGLUT1,GLUT3, andGLUT4 are inhibited by
CB and the intestinal fructose transportersGLUT5 andGLUT7
are not (32). We, therefore, stably transfected HEK293 cells
with GLUT1, GLUT3, or GLUT4 andmeasured the concentra-
tion dependence of WZB117 inhibition of 2-deoxy-D-glucose
(2DG, 0.1 mM) uptake at 37 °C. WZB117 inhibits GLUT1- and
GLUT3-mediated 2DG uptake with Ki(app)  10 M (Fig. 6A)
but is a more potent inhibitor of GLUT4-mediated uptake
(Ki(app) 0.2 M; Fig. 6A).
Heterologous expression of human GLUT1 or GLUT4 (Fig.
6E) significantly reduced endogenous GLUT3 mRNA (Fig. 6B)
and protein (Fig. 6,C andD) levels inHEK293 cells as judged by
qPCR and Western blotting analyses. This explains why high
affinity,WZB117 inhibition of transport inGLUT4-transfected
cells reduced transport more effectively than observed in
untransfected cells (Fig. 6A). We hypothesize that endogenous
GLUT3 expression is reduced in GLUT4- and GLUT1-trans-
fected cells as a compensatory response to increased cellular
sugar uptake.
Molecular Docking Studies—We undertook molecular dock-
ing studies of D-glucose, WZB117, and CB binding to a homo-
logy model of the exofacial (e2) open conformation of GLUT1
(hm-GLUT1-e2). We used the ligand-depleted chain A of the
maltose-bound human GLUT3 (PDB code 4ZWC) structure
(33) as the template to generate the homology model of the
GLUT1-e2 (open) state. GLUT1 and GLUT3 share 65%
sequence identity and 88% sequence similarity (10).
-D-Glucose docks at three high affinity sites in hm-
GLUT1-e2 (Fig. 7a; Fig. 8, a–f). We term these sites peripheral,
intermediate, and core based upon their location within
the exofacial, interstitium-exposed cavity of the GLUT1-e2
conformer. Eighteen -D-Glc binding configurations were
obtained at the core site. The affinity of binding (G) ranged
from	6 to	4 kcal/mol. Of these 18 possibilities, only 4match
the known stereospecificity of sugar inhibition of GLUT1-me-
diated L-sorbose entry in human erythrocytes (34). We illus-
trate one such complex in Fig. 8, e and f. -D-Glc binding at this
site is coordinated by hydrogen bonds toGln161, Gln282, Asn317,
andGlu380. Two additional-D-Glc binding sites were detected
in the exofacial cavity. -D-Glc binding at the peripheral site
(Fig. 8, a and b) and at the intermediate site (Fig. 8, c and d)
presents fewer configurations, and in both instances C1 and its
hydroxyl are solvent-exposed, whereas C6 and its hydroxyl are
not. -D-Glc binding at the intermediate site is coordinated by
hydrogen bonds to Thr30, Asn34, Val69, Ser73, and Asn415. This
orientation of sugar is incompatiblewith the stereochemistry of
L-sorbose uptake inhibition described by Barnett et al. (34).
WZB117 docking studies indicate that WZB117 can assume
three positions in the exofacial cavity of hm-GLUT1-e2. When
binding at its highest affinity site, WZB117 spanned the core
FIGURE 6.WZB117 inhibition of sugar transport is GLUT isoform-specific.
A, Dixonplot of transport inhibitionbyWZB117 inuntransfectedHEK293 cells
(E) and in cells transfected with and expressing hGLUT1 (F), hGLUT3 (‚), or
hGLUT4 (Œ). Ordinate: 1/2DG uptake in min g protein/mol. Abscissa:
WZB117 in M. Lines drawn through the points were computed by linear
regression and Ki(app) for WZB117 inhibition of transport computed as -x-
intercept. The results are: untransfected cells (E), Ki(app) 2.45 0.66 M, R
2
0.975, standard error of regression  3.66 
 1010 min g protein/mol;
hGLUT1-transfected cells (F), Ki(app) 5.71 0.95 M, R
2 0.974, standard
error of regression  7.59 
 109 min g protein/mol; hGLUT3-transfected
cells (‚), Ki(app) 13.32 5.12M, R
2 0.862, standard error of regression
8.82
 109min gprotein/mol; hGLUT4-transfected cells (Œ), Ki(app) 0.23
0.47 M, R2 0.977, standard error of regression 1.09
 1011 min g pro-
tein/mol. B, effect of heterologous GLUT1 or GLUT4 expression on parental
GLUT3mRNA levels as detected by qPCR. For each condition the symbols (F)
show the results of six separate measurements, and the horizontal lines plus
error bars show their mean S.E. The conditions are untransfected (Control),
GLUT1-transfected, and GLUT4-transfected cells. Results are normalized to
one of the six GLUT3 message levels measured in untransfected cells. Ordi-
nary one-way ANOVA shows that GLUT3 mRNA expression is significantly
reduced inGLUT1-transfected andGLUT4-transfected cells relative to control
cells (, p 0.0001;, p 0.0025). C, effect of heterologous GLUT1 or
GLUT4 expression on parental GLUT3 expression. Results are shown for
untransfected (UTF), GLUT1-transfected (G1), and GLUT4-transfected (G4)
cells. Total GLUT3 and NaKATPase expression were assayed by obtaining
whole cell lysates followed by SDS-PAGE of protein load-normalized samples
and immunoblotting using protein-directed antibodies. Molecular mass
markers are shown. D, quantitation of the effect of heterologous GLUT1 or
GLUT4 expression on parental GLUT3 protein levels. Results (normalized to
parental GLUT3 levels in untransfected cells as in Fig. 6 C) are shown for
untransfected (Control), GLUT1-transfected (G1) and GLUT4-transfected (G3)
cells. For each condition the symbols (F) show the results of four separate
measurements, and the horizontal lines plus error bars show theirmean S.E.
Ordinary one-way ANOVA () shows that GLUT3 expression is significantly
reduced in G1 and G4 cells relative to control cells (p 0.0014). E, heterolo-
gous expression of GLUT1 and GLUT4 in HEK293 cells. Results are shown for
untransfected (UTF), GLUT1-transfected (G1), and GLUT4-transfected (G4)
cells. The GLUT1, GLUT4, and NaKATPase contents of protein load-normal-
ized, whole cell lysates were assayed by immunoblot analysis using trans-
porter specific (peptide-directed) antibodies (-GLUT1, -GLUT4, or -Na-
KATPase IgGs) orwithGLUT1andGLUT4byusing-myc IgGs.Molecularmass
markers are shown. Heterologous expression of GLUT1 increasedHEK293 cell
GLUT1 expression over untransfected cells by 47.5- and 30.8-fold using-fold
-GLUT1 and -myc IgGs, respectively. Heterologous expression of GLUT4
increasedHEK293cell GLUT4expressionoveruntransfectedcells by58.7- and
3.6-fold using -GLUT4 and -myc IgGs, respectively.
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and intermediate-D-Glc binding sites (Fig. 7b and Fig. 8, g and
h). Phenol ring 1 occupied the intermediate glucose binding site
and was coordinated by hydrogen bonds to GLUT1 residues
Val69 andAsn415. Phenol ring 2 occupied the core glucose bind-
ing site and was coordinated by hydrogen bonds to GLUT1
residues Asn317 and Glu380 (Fig. 8, g and h). The two lower
affinityWZB117 binding sites comprise one in whichWZB117
docks to and spans the peripheral and core D-Glc binding sites
and a second where WZB117 interacted with the peripheral
and intermediate D-Glc binding sites (not shown). CB did not
dock at any high affinity sites in hm-GLUT1-e2 but did dock to
the endofacial, GLUT1-e1 conformer (GLUT1-e1; Fig. 7d). The
e1 GLUT1 conformation presented overlapping endofacial
WZB117 and D-glucose sites that partially overlapped with the
benzene ring of CB (Fig. 7, c and d).
Discussion
WZB117, a prototypic anticancer drug, inhibited human
erythrocyte sugar transport by acting as a competitive inhibitor
FIGURE 7.Molecular docking studies of ligand binding to hm-GLUT1 and
hm-GLUT4. a, hm-GLUT1-e2 complexed with peripheral, intermediate, and
core -D-glucose molecules (red). GLUT1 is shown in transparent, schematic
representation normal to the bilayer plane (horizontal yellow lines), mem-
brane spanning -helices (H1, H5, H6, H8, H9, and H10) are indicated, and
locations of the interstitium and cytoplasm are highlighted. b, hm-GLUT1-e2
complexed with -D-glucose molecules (red) and WZB117 (green). c, human
GLUT1-e1 conformation complexed with intermediate and core -D-glucose
molecules (red) and WZB117 (green). d, human GLUT1-e1 conformation com-
plexed with -D-glucose molecules (red), WZB117 (green), and CB (yellow). e,
hm-GLUT1-e2 conformation complexed with WZB117. The majority of com-
puted binding sites (28 of 30) overlap with intermediate and core Glc binding
sites. f, hm-GLUT4 e2 conformation complexedwithWZB117. 30 potential bind-
ing sites are indicated; all overlapwith peripheral and core Glc binding sites.
FIGURE 8.-D-Glucose (a–f) andWZB117 (g and h) binding to hm-GLUT1-
e2. The perspective is looking into the exofacial cavity of hm-GLUT1-e2 from
the interstitium. The identities of several membrane spanning  helices (H1,
H2,H4,H5,H7,H9,H11, andH12) are indicated inmagenta ina.-D-Glucose (in
red) is shown docked to the peripheral (a and b), intermediate (c and d), and
core (e and f) sites. ComputedG for ligandbinding: peripheral, D-Glc binding
siteG	5.1 kcal/mol; intermediate D-Glc binding siteG	5.1 kcal/mol;
core binding site  	4.9 kcal/mol. WZB117 is shown in green (g), and its
docking site overlapswith intermediate and core-D-Glc binding sites.G for
WZB117 binding	8.22 kcal/mol. Note that two additional configurations
of WZB117-hm-GLUT1-e2 interactions were observed: one in which WZB117
interactswith and spans peripheral and core-D-glucose binding sites (G
	7.37 kcal/mol) and a second where WZB117interacts only with the periph-
eral and intermediate-D-glucose binding sites (G	6.74 kcal/mol). Bind-
ing is shown as two representations: 1) three-dimensional in which GLUT1 is
represented in transparent schematic format, Glc and WZB117 is in stick for-
mat, and H-bonds are represented as dashed lines (a, c, e, and g); 2) two-
dimensional format in which Glc andWZB117 are shown as two-dimensional
structures, coordinating GLUT1 residues are shown as circles, GLUT1 back-
bones are shown as ribbons, solvent-exposed regions of-D-Glc andWZB117
are indicated by gray-shaded circles, and H-bonds and their directionality are
represented as red arrows (b, d, f, and h).
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of sugar uptake and as a noncompetitive inhibitor of sugar exit.
This suggests that WZB117 and extracellular glucose compete
for binding to the same site on the erythrocyte sugar trans-
porter. Molecular docking and ligand binding studies support
this hypothesis by showing that extracellular D-glucose and
WZB117 binding sites comprise overlapping amino side chains
distinct from those involved in binding CB, an inhibitor that
acts at the endofacial sugar binding site.
Sidedness of Inhibition—Several studies have demonstrated
(regardless of the assumed carrier model) that reversible trans-
port inhibitors binding at the exofacial sugar binding site of the
passive glucose transporters serve as competitive inhibitors of
net sugar uptake and equilibrium exchange transport and as
noncompetitive inhibitors of net sugar exit (23–25). Con-
versely, reversible transport inhibitors binding at the endofacial
sugar binding site are competitive inhibitors of net sugar exit
and equilibrium exchange transport and are noncompetitive
inhibitors of net sugar uptake (23–25). WZB117, therefore, fits
the profile of a reversible inhibitor binding at the exofacial sugar
binding site. CB behaves as a reversible inhibitor that binds at
the endofacial sugar binding site, although themixed-type inhi-
bition of equilibrium exchange sugar transport and our molec-
ular docking studies suggest that CB binding may involve more
than simple interaction with the endofacial sugar binding site.
Determinants of Affinity and Isoform Specificity—Although
several permutations of D-glucose and WZB117 binding sites
were identified in GLUT1 docking studies, the highest affinity
binding sites are consistent with the transport and ligand bind-
ing studies presented here and with previous studies of ligand
binding to GLUT1 (12, 25, 30, 33, 35–37). Three exofacial
D-glucose docking sites are present in the interstitium exposed
exofacial cavity of hm-GLUT1-e2, peripheral, intermediate,
and core. The stereochemistry of sugar binding at the periph-
eral and intermediate sites is incompatible with the findings of
previous studies describing the stereochemistry of sugar trans-
port inhibition by D-glucose analogs (34), whereas several con-
figurations of sugar binding at the core site are compatible with
the earlier studies. We, therefore, propose that the core D-glu-
cose binding site may be the site at which hexose binding sub-
sequently gives rise to sugar translocation.
WZB117 occupies three envelopes in GLUT1-e2. Envelope 1
comprises peripheral and core Glc binding sites, envelope 2
comprises intermediate and core Glc binding sites, and enve-
lope 3 comprises peripheral and intermediate Glc sites. A
majority (93%) of computed WZB117:GLUT1 complexes cor-
respond toWZB117 binding within envelope 2. The remaining
7% are equally distributed between envelopes 1 and 3.WZB117
geometry is fully extended (linear) in envelope 1 but is “L”
shaped in envelopes 2 and 3. Although each envelope would
leave one available Glc binding site available for extracellular
hexose, it is easy to see how Glc and WZB117 would compete
for binding to GLUT1.
CB does not dock to hm-GLUT1-e2 but can be docked with
high affinity to GLUT1-e1. D-Glucose and WZB117 also dock
to GLUT1-e1 but bind at overlapping (and presumably mutu-
ally exclusive) sites deeper within the e1 cavity. These sites do
overlap with the CB binding site, and the observed competi-
tions between sugar, intracellularWZB117, and CB for binding
to GLUT1 suggest that mutually exclusive binding could result
from steric hindrance.
GLUT1 and GLUT3 are inhibited byWZB117 with Ki(app) of
5–10M.GLUT4, the insulin-sensitive glucose transporter of
fat and muscle cells (38–40), is inhibited by WZB117 with a
30–100-fold greater potency.
TheGLUT4-e2 conformer also presents peripheral, interme-
diate, and core Glc binding sites. However, the presence of Ile42
in GLUT4 transmembrane helix 1 (Thr30 in GLUT1 H1) leaves
only linear envelope 1 (peripheral and core Glc sites) accessible
to WZB117 (Fig. 7f). Molecular docking, therefore, suggests
that WZB117 preferentially occupies envelope 2 in GLUT1-e2
and envelope 1 in GLUT4-e2. Km(app) for sugar transport and
Ki(app) for transport inhibition are products of multiple steps in
the catalytic cycle regardless of the presumed mechanism of
transport (25, 41). It is not surprising, therefore, that WZB117
occupancy of different binding envelopes in two transporters
characterized by very different transport kinetics (42) would
result in significantly different Ki(app) for sugar transport
inhibition.
Implications for Mechanism of Passive Sugar Transport—
Four observations in the present study impact our understand-
ing of glucose transport mechanism as follows. 1) As is the case
for extracellular D-glucose (30), extracellularWZB117 does not
affect CB binding to GLUT1. Hence, the transporter’s exofacial
sugar/WZB117 binding site and the endofacial CB binding site
are not mutually exclusive. If CB binds only to the GLUT1-e1
conformer,which presents an endofacial sugar binding site, this
behavior refutes the simple (alternating conformer) carrier
model for sugar transport which predicts that inhibitor binding
to the exofacial sugar binding site should competitively inhibit
CB binding (43–45). 2) Extracellular WZB117 does not
increase Ki(app) for CB noncompetitive inhibition of sugar
uptake. Again, if CB binds only to the endofacial e1 conformer
of GLUT1, this observation refutes the simple (alternating con-
former) carrier model for sugar transport (43–45). 3) Like
extracellular maltose and intracellular CB (27, 28), subsaturat-
ing extracellular WZB117 modestly stimulates sugar uptake.
Transport stimulation by exofacial and endofacial transport
inhibitors has been ascribed to cooperative interactions
between co- existent exofacial and endofacial sugar binding
sites present in the tetramericGLUT1 transporter complex (27,
28). The transporter is proposed to comprise four subunits
(GLUT1 proteins) in which each subunit behaves as an alter-
nating conformer carrier but where intersubunit cooperativity
results in two subunits presenting exofacial (e2) orientations
and 2 subunits presenting endofacial (e1) conformations at any
instant (46, 47). At subsaturating WZB117, there is a greater
probability that only one of the two available GLUT1-e2 con-
formers is occupied byWZB117, and its occupancy is proposed
to allosterically activate sugar uptake via the remaining, inhib-
itor-free e2 subunit (28). As WZB117 is further increased, the
probability that inhibitor occupies both e2 subunits increases
and leads to sugar uptake inhibition. An alternative hypothesis
is that exofacial ligand-induced allostery is an intrasubunit phe-
nomenon in which occupancy of the exofacial cavity by poly-
phenolicWZB117 increasesGLUT1affinity for, or transport of,
the transported sugar through the sameGLUT1 subunit (48). 4)
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Molecular docking studies reveal three exofacial D-glucose
binding sites in the hm-GLUT1-e2 cavity, peripheral, interme-
diate, and core. This is consistent with previous observations
thatGLUT1binds2mol of transported sugar permolGLUT1
(49). Each envelope would leave one Glc binding site available
for substrate. The results of this docking analysis, therefore, do
not permit resolution of the mechanism of exofacial allostery
(i.e. inter- or intrasubunit interactions).
Implications for Use as an Anticancer Agent—Although a
promising strategy for cancer cell elimination, glucose trans-
port inhibition usingWZB117 could perturb organismal carbo-
hydrate homeostasis in several important ways. Blood-brain
and blood-tissue barrier GLUT1-dependent glucose transport
will be depressed, perturbing peripheral and central neuro-
metabolic function (50). Human, GLUT1-dependent, pancre-
atic beta cell insulin secretion in response to hyperglycemia will
be diminished (51), and insulin-dependent, GLUT4-mediated
skeletal muscle and adipose glucose transport will be prone to
high affinityWZB117 inhibition thereby further compounding
hyperglycemia. The net effects will include acute hyperglyce-
mia and perturbations of neurometabolic function and insulin-
dependent lipogenesis. These predictions are consistent with
the reported hyperglycemia and lipodystrophy in mice after
WZB117 treatment (9) and suggest that WZB117-treatment
could inducemetabolic syndrome/insulin resistance in individ-
uals undergoing therapy.
The current study demonstrates thatWZB117 inhibits facil-
itative sugar transport by competing with sugars for occupancy
of the exofacial substrate binding site of the transporter.
GLUT1, GLUT3, and GLUT4 are sensitive to transport inhibi-
tion, suggesting that sugar transport across the blood brain bar-
rier in CNS astrocytes and neurons and in insulin-sensitive tis-
sues is susceptible to inhibition (52). Most cancer cells rely
on anaerobic glycolysis to generate the ATP and substrates
required for cellular processes and proliferation (1). This con-
trasts with normal, differentiated cells, which mostly use mito-
chondrial oxidative phosphorylation to sustain cellular func-
tion (2). This could explain why sugar transport inhibition is a
successful anti-cancer strategy in mice (9). However, human
CNS development and function are especially dependent on
glucose transport and metabolism (50), and the consequences
of inhibition of glucose transport into and within the CNS
could be catastrophic. We suggest, therefore, that a combina-
tion therapy of ketogenic diet (such as is used to manage
GLUT1 deficiency; Refs. 4 and 53–55) plus sugar transport
inhibition might be more successful.
Experimental Procedures
Reagents—([3H]Cytochalasin B and 3-O-[3H]methylglucose
([3H]3MG) were purchased from American Radiolabeled
Chemicals (St. Louis, MO). Unlabeled 3MG, CB, and phloretin
were purchased from Sigma. WZB117 was purchased from
EMDMillipore (Billerica, MA).
Solutions—KClmediumwas composed of 150mMKCl, 5mM
HEPES, 4mMEGTA, 5mMMgCl2, pH 7.4. Solubilization buffer
was composed of KCl medium with 0.5% Triton X-100. Phos-
phate-buffered saline was composed 140 mM NaCl, 10 mM
Na2HPO4, 3.4mMKCl, 1.84mMKH2PO4, pH 7.3. Stop solution
was composed of ice-coldKClmediumplusCB (CB; 10M) and
phloretin (100 M). Sample buffer contained 0.125 M Tris-HCl,
pH 6.8, 4% SDS, 20% glycerol, and 50 mMDTT. Transfer buffer
was composed of 12 mM Tris base, 96 mM glycine, 20%
methanol.
Cells—De-identified whole human blood was purchased
from Biological Specialty Corporation (Colmar, PA). HEK293
cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum, 100
units/ml penicillin, and 100 g/ml streptomycin in a 37 °C
humidified 5% CO2 incubator. Resealed, human red cell ghosts
weremade as described in Sage and Carruthers (56), and eryth-
rocyte membranes were depleted of peripheral membrane pro-
teins and resuspended in KCl medium at 4 mg protein/ml as
described in Carruthers (57).
Heterologous Expression of GLUTs—GLUT1, GLUT3, and
GLUT4 heterologous expression in HEK293 cells was as
described previously (42, 58). BothGLUT1 andGLUT3 contain
a myc-epitope in exofacial loop 1 (42). GLUT1, GLUT3,
GLUT4, and NaKATPase expression in whole cell lysates was
analyzed by Western blotting as previously described (42, 58).
Erythrocyte Sugar Transport Measurements—All human red
cell sugar transport experiments were performed at 4 °C as pre-
viously described (15, 59, 60).
Zero-trans Uptake—Five volumes (100 l) of 3MG uptake
medium WZB117 or CB were added to 1 volume (20 l) of
sugar-depleted, 50%hematocrit (Ht) red cells, and sugar uptake
allowed to proceed for 0.5–1 min at 4 °C. Uptake was stopped
by adding 50 volumes (1 ml) of ice-cold stop solution contain-
ing 100 M phloretin and 10 M CB. Cells were washed in stop
solution and lysed in 3% perchloric acid, and centrifugation-
clarified lysates were assayed for radioactivity in duplicates
using liquid scintillation counting.
Zero-trans Exit—Sugar-depleted packed RBCs were loaded
with 10 mM 3MG by incubating with 20 mM 3MG (containing
10 Ci [3H]3MG/10 ml of cold 3MG for 1 h at 37 °C). One
volume (0.5ml) of sugar-loaded RBCs was added to 50 volumes
of KCl medium  CB or WBZ117 on a shaker with magnetic
stirrer. Aliquots (0.5 ml) of the suspension were withdrawn at
the indicated time intervals, washed in ice-cold stop solution,
lysed, and assayed for remaining radioactivity.
Equilibrium Exchange Transport—Sugar-depleted RBCs
were preloadedwith 2.5–50mM3MGat 25 °C for 30min.These
cells were collected by centrifugation, incubated in 10 volumes
of 3MGWZB117 or CB for 10min at 4 °C, centrifuged again,
and resuspended to 50% Ht in the appropriate 3MG and inhib-
itor medium. 3MG uptake medium (100 l)WZB117 or CB
was added to 20 l of sugar-loaded cells (50% Ht), and the
experiment was allowed to proceed for 0.5–1 min at 4 °C.
Uptake was arrested by adding 50 volumes (1 ml) of ice-cold
stop solution. Cells were centrifuged, and the pellet was washed
in 1 ml of stop solution, collected by centrifugation, lysed in 3%
perchloric acid, clarified, and assayed for radioactivity in dupli-
cates using liquid scintillation counting.
HEK293 Cell Sugar Transport Measurements—All HEK293
cell sugar transport experiments were performed at 37 °C using
0.1 mM 2-deoxy-D-glucose as previously described (42, 58).
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CB Binding—Equilibrium CB binding to red cells and to red
cell membranes depleted of peripheral membrane proteins was
performed as previously described (30). Briefly, 1 volume of
sugar-depleted red cells (50% Ht) or red cell membranes (4 mg
of membrane protein/ml) was suspended in one volume of ice-
cold wash buffer 150mMKCl, 5 mMHEPES, pH 7.4, containing
0.5 M [3H]CB, 10 M cytochalasin D, and varying concentra-
tions of WZB117 (1–60 M) for 15 min at 4 °C with constant
end-over-end rotation. For total CB, 2 
 10 l of the cell sus-
pension were lysed in 100 l of 3% perchloric acid and clarified
by centrifugation, and the associated radioactivity was assayed
by liquid scintillation counting. For free CB, the cell suspension
was centrifuged at 10,000 
 g for 30 s, and 10 l of clarified
supernatant were assayed in duplicate by scintillation counting.
Bound CB was obtained as: total CB	 free CB.
Quantitative RT-PCR—Expression levels of hGLUT3mRNA
weremeasured by qPCRusing theQuaniTect SYBRGreen PCR
kit (Qiagen). Reactions were performed according to the man-
ufacturer’s protocol. Total RNA was isolated from HEK293
cells stably overexpressing hGLUT1 or hGLUT4 using the
RNeasy kit and Qiashredder (Qiagen). cDNA was synthesized
using theQuantiTect ReverseTranscriptase kit (Qiagen). qPCR
reactions contained 100 ng of the indicated cDNA and 0.3 M
each human GLUT3-specific qPCR primers (G3, 5-qF-
AGCTCTCTGGGATCAATGCTGTGT and G3 3qR-ATG-
GTGGCATAGATGGGCTCTTGA, where qF denotes qPCR
forward and qR denotes qPCR reverse). Samples were run in
triplicate on a Research PTC-200 Peltier Thermal Cycler
with a Chromo4 real time PCR detector running Opticon
Monitor 3 software (Bio-Rad). Results were analyzed by
using the Ct method and normalized to an internal
GAPDH marker.
Data Analysis—Linear and nonlinear regression analysis of
data sets and statistical tests were accomplished using
GraphPad Prism (Version 7.0a; La Jolla, CA).
Michaelis-Menten inhibition of sugar transport is assumed
to be described by
v  v0 
v0I
K i(app)	 I
(Eq. 1)
uptake, where vo is vmeasured in the absence of inhibitor I, [I]
is the concentration of inhibitor andKi(app) is that [I] producing
50% inhibition of uptake.
Michelis-Menten transport is assumed to be described by
v 
Vmax3MG
Km(app)	 3MG
(Eq. 2)
uptake, where Vmax is the maximum rate of 3MG transport,
[3MG] is the concentration of 3MG, and Km(app) is that [3MG]
where the rate of uptake is Vmax/2.
Hanes-Woolf analysis of transport assumes Michelis-Men-
ten kinetics, and when data are plotted as [3MG]/v versus
[3MG], the results fall on a straight line described by
3MG
v

3MG
Vmax
	
Km(app)
Vmax
(Eq. 3)
where Vmax is the maximum rate of 3MG transport, [3MG] is
the concentration of 3MG, andKm(app) is [3MG], where the rate
of uptake is Vmax/2.
Transport stimulation followed by inhibition by inhibitors
was approximated first by normalizing all uptake to vo and then
using the following model.
v
v0
 1 	
I1
K1 	 I
 I
1 	 1
K2 	 I
(Eq. 4)
HomologyModeling—The homologymodels of the e2 (open)
state of GLUT1 and GLUT4 were generated using the maltose-
bound human GLUT3 (PDB code 4ZWC) structure (33).
GLUT1 and GLUT3 have 65% sequence identity and 88%
sequence similarity (10). Ligands were removed, and chain A
was used as the template for eachmodeled structure. Sequence
alignments were generated using ClustalX. Homology models
were built using Modeler-9.9 and analyzed using PROCHECK.
The GLUT1-e1 structure (PDB code 4PYP; Ref. 61) was used
directly.
Stochastic Docking—The GLUT1 crystal structure was
obtained from the protein data bank using PDB code 4PYP. The
structures for -D-glucose and CB were obtained from ZINC.
The WZB117 structure was generated using the three-dimen-
sional structure generator Corina from Molecular Networks
GmbH. Docking was performed using the Schrodinger soft-
ware suite. The protein structure was preprocessed with the
Protein PreparationWizard, bond orderswere assigned, hydro-
gens were added, and the H-bond network was optimized. The
system was energy-minimized using the OPLS 2005 force field.
Ligand structures were prepared with the LigPrep module, and
the pKa of the ligands was calculated using the Epik module.
Computational docking was performed by the GLIDE module
in standard precision (SP) mode and default values for grid
generation. Cavities for docking were calculated using the
CastP server, and the grid was centered on the residues forming
the cavity. No restraints were used during the docking.
Author Contributions—O. O. conducted most of the experiments,
analyzed the results, and wrote most of the paper. K. L. undertook
the molecular docking studies. A. S. assisted with the quantitative
analysis of data. J. D. conducted the experiments on the isoform
specificity of WZB117 inhibition of transport. A. C. conceived the
idea for the project and co-wrote the paper with O. O.
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